Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allscripts' TouchScript In 400 Practices: $1.3 Mil. From System Sales In 1999

Executive Summary

Allscripts' TouchScript hand-held prescribing devices are in use in over 400 physician practice sites six months after its deployment, according to a Feb. 18 prospectus for a 2 mil.-share secondary offering.

You may also be interested in...



PocketScript Uptake Will Be Supported By Pharma Promotion

PocketScript plans to put over 1,000 prescribing devices in physicians' hands with support from four pharmaceutical companies.

PocketScript Uptake Will Be Supported By Pharma Promotion

PocketScript plans to put over 1,000 prescribing devices in physicians' hands with support from four pharmaceutical companies.

Allscripts, iScribe And ePhysician Racing To Put Script Devices In MD Hands

Allscripts is seeking early market experience in Silicon Valley with its TouchScript hand-held prescribing device.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel